BTAI BioXcel Therapeutics
- 2.120
- -0.230-9.79%
- 2.160
- +0.040+1.89%
BioXcel Therapeutics News
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in n
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ETTrial being led by Georgetown University's Lombardi Comprehensive Cancer CenterNEW HAVEN, Conn., April 24, 2024 (GLOBE N
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.
BioXcel Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 250.88% HC Wainwright & Co. → $10 Reiterates Buy → Buy 03/18/2024 285.96% HC Wainwright & Co. →
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment
BioXcel Therapeutics (BTAI) said Monday it plans to initiate an at-home phase 3 trial of BXCL501, a potential treatment for agitation linked to bipolar disorder or schizophrenia, based on the US Food
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
BioXcel Therapeutics Reveals Plan For Evaluating BXCL501 In The At-Home Setting To Expand Its Market Potential
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDANo FDA-approved therapies for acute treatment of agitation associated with bi
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,811.54 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Yocca Frank sold 1,067 shares of common stock on Apr 4, 2024 at an average price of $2.635 for a total value of $2,811.54.Source: Announcement What is statement
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,816.81 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Steinhart Richard I sold 1,069 shares of common stock on Apr 4, 2024 at an average price of $2.635 for a total value of $2,816.81.Source: Announcement What is s
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,667.43 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Rodriguez Javier sold 1,012 shares of common stock on Apr 4, 2024 at an average price of $2.6358 for a total value of $2,667.43.Source: Announcement What is sta
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,656.18 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Wiley Matthew T. sold 1,008 shares of common stock on Apr 4, 2024 at an average price of $2.6351 for a total value of $2,656.18.Source: Announcement What is sta
BioXcel Therapeutics(BTAI.US) Officer Sells US$13,823.02 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Mehta Vimal sold 5,268 shares of common stock on Apr 4, 2024 at an average price of $2.624 for a total value of $13,823.02.Source: Announcement What is statemen
BioXcel Therapeutics(BTAI.US) Officer Sells US$432.48 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer O'Neill Vincent sold 165 shares of common stock on Apr 4, 2024 at an average price of $2.6211 for a total value of $432.48.Source: Announcement What is statemen
Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis
Analysis
Price Target
No Data
